Newer therapeutic approaches: spondyloarthritis and uveitis.
Over the last 5 years considerable progress has taken place in the therapeutic approach to spondyloarthritis (SpA). This progress is due in large part to the development of effective biologic therapies and to improved clinical trial design and implementation. This article summarizes treatment advances in SpA with emphasis on the efficacy and safety of biologic agents in the treatment of psoriatic arthritis, ankylosing spondylitis, undifferentiated spondyloarthropathy, and uveitis.
Ritchlin
Christopher
C
Clinical Immunology Research Unit, Allergy/Immunology and Rheumatology Division, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. christopher_ritchlin@urmc.rochester.edu
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D025241:Spondylarthritis / Q000628:therapy*; D016896:Treatment Outcome; D014605:Uveitis / Q000628:therapy*
D000900:Anti-Bacterial Agents; D018501:Antirheumatic Agents; D007155:Immunologic Factors